Milestones

ADVANCES IN WHICH
UCSF CARDIOVASCULAR RESEARCH INSTITUTE
HAS PLAYED A MAJOR ROLE

1958

Catheterization for diagnosis of congenital cardiac anomalies.

Revolutionized diagnosis and treatment of congenital heart disease.

 

1961-1972

Pulmonary surfactant.

Discovered, characterized, and developed as therapy for respiratory distress syndrome in premature infants. Decreased overall infant mortality.

1976

Indomethacin for patent ductus arteriosus closure.

Allows infants with this congenital abnormality to avoid major surgery.

1981

Catheter-based ablation therapy for cardiac arrhythmias.

Cures some types of heart-rhythm problems without need for open-heart surgery.

1976-80

Role of diastolic dysfunction in heart failure.

Improved understanding and treatment of heart failure.

1987

ACE inhibitors in heart failure.

Contributed to this application of ACE inhibitors, which improve and extend lives of heart-failure patients.

1988-1998

Eptifibatide.

Used in approximately one million patients each year to prevent clotting during angioplasty and interrupt developing heart attacks.

1991

Identification of thrombin receptor.

Enabled development of new and potentially revolutionary class of clot-preventing drugs now in clinical trials.

1992

Identification of VEGF receptor.

Enabled development of Avastin and other inhibitors of tumor blood vessel growth. .

1994

Identification of monocyte chemoattractant protein receptor.

Enabled development of new class of anti-inflammatory drugs now in clinical trials.

1995

Catheter-based aortic aneurysm repair and other surgical innovations.

Allows some patients to avoid major surgery and allows repairs not previously possible.

1997

Roles of IgE and inflammation in asthma; proof of concept for Xolair.

Key steps in developing new class of asthma drug.

2001

Low tidal volume ventilation in adult respiratory distress syndrome.

Decreases mortality in patients with respiratory distress syndrome.

2002

Roles of collectins in host defense.

May enable development of new class of antimicrobial agents.

2000-2006

High throughput genotyping (HapMap).

Enabled new level of genetic research that will lead to tailoring measures to prevent heart attacks to a patient’s particular risk factors and more precise prevention, diagnosis, and treatment of heart-rhythm problems.

CVRIHead